Ependymoma, Recurrent Recruiting Phase 2 Trials for Vemurafenib (DB08881)

Also known as: Ependymoma Recurrent / Recurrent Ependymoma

IndicationStatusPhase
DBCOND0106575 (Ependymoma, Recurrent)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening